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Objective: To determine whether FDG PET/CT was more sensitive than CT in detecting
metastatic disease in the cardiophrenic space and whether the presence of disease in this
location would change the staging and clinical management.
Materials and Methods: About 1200 PET/CT scans were retrospectively reviewed over
20 months for the presence of FDG-avid cardiophrenic lymph nodes. The SUVmax was
used to quantify the metabolic activity in each of the lymph nodes. The radiographic data
was used for correlation. A retrospective review of diagnostic CT reports performed within
a 1-month period of time of the PET/CT in the same subset of patients determined whether
cardiophrenic lymph nodes were mentioned.
Results: About 9 (0.8%) of the 1200 studies were found to have FDG-avid cardiophrenic
lymph nodes (four males and five females with a mean age of 55 years; range 7–69, median
59).The mean SUVmax was 2.4 (range 1.2–7.9; median 1.9). Only three of the patients were
found to have suspicious lymph nodes on CT. The presence of cardiophrenic lymph nodes
had the potential to change the staging and/or management in three of the patients.
Conclusion: PET/CT is more accurate in the detection of pathologic cardiophrenic lymph
nodes than CT, especially when they are subcentimeter in size. When present, staging
and/or management was potentially affected in 33%. Therefore, these nodes should be
included in the TNM staging classification.
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INTRODUCTION
The presence or absence of disease within lymph nodes has impor-
tant prognostic significance in patients with known malignancy as
it can alter the stage of their disease and even change management
from surgical cure to non-surgical management. The numerous
locations of lymph nodes and their various implications in disease
staging has been well-documented in the TNM classification sys-
tem for many types of cancers, and while abnormal mediastinal
lymph nodes play a critical part in the staging of diseases, such
as lung cancer, lymphoma, ovarian cancer, or other extrathoracic
primary malignancies, very little has been done to determine the
importance of cardiophrenic lymph nodes in disease staging. In
fact, there is very little data in the literature on what constitutes
a normal sized cardiophrenic lymph node. Also, while metastatic
disease involvement of the cardiophrenic lymph nodes is a well-
documented phenomenon in ovarian cancer, these nodes are not
included in the lymph node maps of the most recent IASLC for
lung cancer staging (1).
Computed tomography (CT) is routinely used in the evaluation
of and treatment planning for patients with malignancy as well
as for surveying patients for recurrent disease. 18-FDG Positron
Emission Tomography/Computed Tomography (PET/CT) is also
used for these purposes and is predominantly used to determine
the extent of disease involvement and evaluate for the presence of
distant nodal metastases. The cardiophrenic angle is an area that
is often overlooked on routine CTs, especially since there is such
variability in their presence and size. PET/CT, on the other hand, is
able to detect abnormal FDG activity in a very small node without
being limited by size criteria.
The purpose of this study was to determine whether PET/CT
is more sensitive than CT in detecting metastatic disease in the
cardiophrenic space and whether the presence of disease in this
location would change the staging and clinical management of
patient with malignancy.
MATERIALS AND METHODS
PATIENT SELECTION
A retrospective review of 1200 consecutive FDG PET/CT reports of
cancer patients in the span of 20 months was performed to detect
the presence of FDG-avid cardiophrenic lymph nodes. The max-
imum standardized uptake value (SUVmax) was used to quantify
the metabolic activity in each of the lymph nodes. The radi-
ographic data was used for correlation. A retrospective review
of diagnostic contrast-enhanced CT reports performed within a
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1-month period of time of the PET/CT in the same subset of
patients determined whether the cardiophrenic lymph nodes were
mentioned. Only one of the CTs was performed without contrast.
PET/CT SCANNING
An intravenous 5.18 MBq/kg (0.14 mCi/kg) injection of 18F-FDG
was administered after the patient had fasted at least 4 h. Patients
sat in a quiet room without talking during the subsequent 60 min
of the FDG uptake phase. Blood glucose level was <200 mg/dl
in all patients. All scans were acquired using a PET/CT scanner
(Gemini TF; Philips Medical Systems) with an axial co-scan range
of 193 cm.
CT SCANNING
The CT component of the PET/CT scanner consisted of a 64 slice
multidetector helical CT with a gantry port of 70 cm. Parameters
were as follows for 20–21 bed acquisitions: 120–140 kV and 33–
100 mAs (based on body mass index), 0.5 s per CT rotation, pitch
of 0.9, and 512× 512 matrix. CT data were used for image fusion
and the generation of the CT transmission map. In all patients,
the arms were placed above the patient’s head for CT acquisition
except in patients with head and neck cancers where the arms were
placed at the patient’s sides. The CT images were obtained without
oral or IV contrast.
PET SCANNING AND IMAGE PROCESSING
The PET component of the PET/CT scanner is composed of
Lutetium-Yttrium Oxyorthosilicate (LYSO)-based crystals. Emis-
sion data were acquired on average for 20–21 bed positions
(193 cm coverage, identical to the CT protocol). Emission scans
were acquired at 1–2 min per bed position. The FOV was from
the top-of-head to the bottom-of-feet in all patients. The 3-
dimentional whole body (WB) acquisition parameters consisted
of a 128× 128 matrix and an 18 cm FOV with a 50% overlap.
Processing consisted of the 3D Row Action Maximum Likelihood
Algorithm (RAMLA) method (2). Total scan time per patient was
20–45 min.
IMAGE ANALYSIS
PET/CT images of the nine patients included were retrospec-
tively evaluated on the Gemini TF extended brilliance workstation
(EBW) by two board certified nuclear medicine physicians. A log
recorded reports which documented the presence of cardiophrenic
lymph nodes based on PET and unenhanced CT. When seen, the
size and SUVmax of the lymph nodes were obtained. Cardio-
phrenic lymph nodes were defined as those lymph nodes located
anterior to the pericardium and within 2 cm of the diaphragm.
These have alternatively been described as anterior prepericardiac
nodes and are responsible for draining the diaphragm, pleura,
anterior abdominal wall, and liver through the internal mammary
chain (3). No minimum size,number,or standardized uptake value
criteria was assigned to the lymph nodes for inclusion into the
study. Recent CT reports were then reviewed to determine whether
the cardiophrenic lymph nodes were seen and mentioned in the
CT report. A thorough review of the medical record including
all clinical notes and radiology reports was performed on each
patient to determine the type of malignancy and any planned or
completed methods of treatment.
RESULTS
Of the 1200 patients evaluated, 9 (0.8%) were found to have FDG-
avid cardiophrenic lymph nodes (four males and five females with
a mean age of 55 years; range 7–69; median 59). On the CT por-
tion of the PET/CT the nodes demonstrated a mean size of 0.8 cm
in the short axis diameter (range 0.4–1.6 cm; median 0.7 cm). The
mean SUVmax was 2.5 (range 1.2–7.9; median 1.9). Only three
of these patients were found to have suspicious lymph nodes on
CT (two contrast-enhanced CT, one non-contrast CT). The pres-
ence of cardiophrenic lymph nodes did not affect the staging and
management in six out of the nine patients as they already had
widely metastatic disease, but their presence did have the poten-
tial to affect staging in the remaining three patients. The table
summarizes the disease processes and lymph node characteristics
(Table 1).
The size of the lymph nodes did not have an impact on the
suspicion of disease involvement as many of the lymph nodes
were <0.5 cm (39%). However, the likelihood of disease in the
lymph nodes was thought to directly correlate to the SUVmax
value (Figure 1). The presence of more than one cardiophrenic
lymph node was also considered to be more indicative of disease
involvement.
None of the patients underwent biopsy of the cardiophrenic
lymph nodes. As a result, pathologic correlation was not available.
However, most of the patients had biopsy-proven malignancies
from other sites. These included squamous cell carcinoma of the
lung, pancreatic adenocarcinoma, large B-cell lymphoma, and T
cell lymphoma. One of the patients did undergo biopsy of several
lung lesions which were pathologically proven to be necrotizing
granulomas. This patient had a complex history including HIV
and previously treated cavitary squamous cell carcinoma of the
lung, and the presence of FDG-avid cardiophrenic lymph nodes
may have been a result of granulomatous disease or recurrent
cancer. Subsequent studies on this patient over the course of
22 months demonstrated no change in size of the lymph node with
a gradual decrease in activity thereby making an inflammatory
process more likely. An additional patient had a primary diagnosis
of glioblastoma multiforme (GBM) of the brain with additional
findings of splenomegaly, multiple enlarged abdominal lymph
nodes, and several FDG-avid cardiophrenic lymph nodes. This
patient died before workup of a possible diagnosis of lymphoma
was able to be performed. In this patient, the presence of supradi-
aphragmatic FDG-avid lymph nodes could have affected staging
if an additional primary malignancy was able to be diagnosed. A
third patient was found to have biopsy-proven squamous cell carci-
noma of the right lung with ipsilateral mediastinal and subcarinal
lymph node involvement. In addition, the patient had ipsilateral
FDG-avid cardiophrenic lymph node involvement (Figure 2). The
TNM classification for lung cancer does not include cardiophrenic
lymph nodes in its staging map. It is unclear whether the presence
of this abnormal lymph node had the potential to change the
staging in this patient.
DISCUSSION
Most solid lesions detected within the cardiophrenic space rep-
resent lymph nodes. More often than not, the presence of these
lymph nodes is abnormal and should be evaluated further for
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Table 1 | Summary of patient and lymph node characteristics.
Age
(years)
Sex Type of cancer Size of cardiophrenic
lymph nodes (cm)
SUVmax of cardiophrenic
lymph nodes
56 M Lung squamous cell carcinoma; also history of HIV and granulomatous disease 0.4 1.5
52 F Pancreatic adenocarcinoma 0.4, 0.4 2.3, 1.6
59 M Glioblastoma multiforme 1.5, 1.6, 1.6 1.6, 0.7, 0.6
63 M Large B-cell lymphoma 0.8 1.6
56 F Lung squamous cell carcinoma 0.9, 0.6, 0.5 3.0, 1.2, 2.0
7 F T cell lymphoma 0.8 3.0
68 F Pancreatic adenocarcinoma 0.7, 0.6 3.9, 2.9
72 F Large B-cell lymphoma 0.4, 0.5, 0.8, 0.5 1.8, 2.3, 7.9, 1.4
63 M Pancreatic adenocarcinoma 1.1 3.8
FIGURE 1 | Seventy-two year-old female presenting with metastatic
pancreatic adenocarcinoma. PET/CT demonstrates an FDG-avid
cardiophrenic lymph node on non-contrast CT (top left), PET (top right), and
fused images (bottom left). These were not commented on in the
contrast-enhanced CT (bottom right). Differences in the levels between the
two studies are due to patient positioning and respiratory motion.
malignancy from primary tumors (supra- or infra-diaphragmatic)
(4). Usually, the underlying etiology is lymphoma since there is
a large lymphatic drainage system located along the diaphragm.
Alternatively, since this region is also responsible for abdominal
lymphatic drainage, numerous abdominal neoplasms can metas-
tasize to the cardiophrenic region. In addition, primary lung
or pleural malignancies can spread via the supradiaphragmatic
lymph nodes. Since dissemination of tumor into lymph nodes usu-
ally implies metastatic disease, their presence commonly affects
the treatment of the patient (4). Furthermore, involvement of
these lymph nodes by lymphoma has been shown to be infre-
quent; therefore, their presence is important to document as one
study found it altered treatment (5, 6).
Also, while small lymph nodes in this region may be a normal
finding, there is very little data on what size actually constitutes
an abnormal lymph node. Aronberg et al. proposed a cutoff of
5 mm for a normal cardiophrenic lymph node. He noticed that
nodes >6 mm were seen in patients with diseases associated with
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FIGURE 2 | Fifty-six year-old female with a history of squamous cell
carcinoma of the right lung. PET/CT demonstrates an FDG-avid
cardiophrenic lymph node on non-contrast CT (top left), PET (top right), and
fused images (bottom left). These were not commented on in the
contrast-enhanced CT (bottom right). Differences in the levels between the
two studies are due to patient positioning and respiratory motion.
lymphadenopathy (7). Sussman et al. on the other hand, suggested
a size of 1 cm as the upper limit of normal unless more than one
cardiophrenic lymph node measuring <1 cm was present which
would then be considered suspicious (3). Subsequently, Dorfman
et al. reviewed previous studies evaluating the size of paracardiac
lymph nodes defined as those within 2 cm of the diaphragm and
adjacent to the pericardium and found a range for normal lymph
nodes of 2–8 mm in the short axis diameter (2). His conclusion
was that lymph nodes that exceeded a short axis diameter of 8 mm
in the paracardiac region were abnormal and should be consid-
ered suspicious, especially if more than one node was present (2).
If a size >0.8 cm had been used as a cutoff for suspecting dis-
ease within a lymph node in this study, multiple abnormal lymph
nodes would have been missed. In fact, many of the abnormal
lymph nodes were <0.8 cm (72%). Furthermore, all but three of
these lymph nodes were missed on the CT studies. The three that
were reported on the CTs measured 1 cm, 1.4 cm, and 0.5 cm sug-
gesting that most were identified simply because of their larger
size. The additional use of FDG PET allowed for the detection
of abnormal activity within the lymph nodes thereby increasing
the likelihood of disease involvement. The presence of more than
one lymph node, regardless of size, was also more likely to imply
pathology. The degree of SUV uptake appeared independent of
the lymph node size; however, the degree of uptake did appear
to correlate with the likelihood of pathology in the lymph node.
For example, multiple subcentimeter cardiophrenic lymph nodes
were seen in a patient with known large B-cell lymphoma who was
being evaluated after therapy. Four lymph nodes (size 0.4–0.8 cm)
demonstrated variable activity (SUVmax 1.4–7.9) suspicious for
disease progression.
This study finds that PET/CT is much better than contrast-
enhanced CT at detecting pathology in smaller cardiophrenic
lymph nodes. It also finds that size alone is not adequate for rul-
ing out pathology in lymph nodes in the cardiophrenic region as
lymph nodes as small as 0.4 cm can harbor disease.
The presence of abnormal cardiophrenic lymph nodes had the
potential to change staging in three of the nine patients in this
study. The most significant potential was in a patient with squa-
mous cell carcinoma of the right lung (maximum diameter 7.5 cm)
who also had ipsilateral mediastinal and subcarinal lymph node
involvement. Normally, this patient would have been classified as
Stage IIIA by the TNM staging system and would, therefore, be
able to potentially undergo resection (8). However, the presence
of disease in several cardiophrenic lymph nodes has the potential
to alter the staging to a Stage IIIB or Stage IV, thus rendering the
treatment as non-operable. Unfortunately, the IASLC lung can-
cer staging project does not include cardiophrenic lymph nodes
in the nodal staging map. Potential classifications would be to
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characterize the nodal staging based on whether the cardiophrenic
nodes are ipsilateral or contralateral, and, if contralateral, should
they be classified as a N3 lesion or as a M1 lesion.
Another problem in determining whether a cardiophrenic
lymph node harbors disease is that it is a location that is not
easily biopsied. Oftentimes, this deters physicians from trying
to sample tissue from these nodes. However, in the situation in
which this is the only abnormal lymph node, biopsy becomes a
necessity for treatment planning. Several reports document the
findings of abnormal cardiophrenic lymph nodes representing
metastases, either isolated or multiple, from various gynecologic
malignancies, most commonly epithelial ovarian carcinoma (9–
11). The presence of these lymph nodes had variable prognostic
significance depending largely on the presence of additional dis-
ease involvement, such as peritoneal metastasis or other abnormal
extra-abdominal lymph nodes. The most commonly used method
to biopsy these lymph nodes in the past has been video-assisted
thoracic surgery (VATS). For patients undergoing cytoreductive
surgeries for ovarian cancer, this meant an additional surgery.
Recently, a newer method has been described which is performed
at the same time as the cytoreductive surgery. A small incision
is made in the diaphragm in order to biopsy the abnormal car-
diophrenic nodes (transabdominal cardiophrenic lymph node
dissection or CPLND) (12). This method may potentially be
performed in other abdominal malignancies in which the car-
diophrenic lymph node may represent a change in staging and
a surgery is already being performed in the abdomen, such as
in lymphoma, hepatocellular carcinoma, pancreatic adenocar-
cinoma, etc. (13). Furthermore, if large enough, these lymph
nodes could potentially be biopsied safely using ultrasound
guidance.
This study does have some limitations. First, the study only
selected studies in which the words “cardiophrenic lymph node”
were mentioned in the report. As a result, there may have been
some studies that were missed if the nodes were referred to by
another name, such as paracardiac, supradiaphragmatic, or peri-
cardial. Similarly, any FDG-avid cardiophrenic lymph nodes not
detected in the reading of a PET/CT would also not be included,
and there is no way to estimate the number of these possible cases.
The study is also limited by its small sample size. In addition, none
of the cardiophrenic lymph nodes in the patients studied had biop-
sies of the nodes performed to confirm the presence of disease.
Also, of the patients died before workup of a possible lymphoma
could have been performed. Therefore, no pathologic process was
proven in this patient other than the primary brain malignancy
(GBM). Furthermore, another patient had a history of both lung
cancer and granulomatous disease. The abnormal cardiophrenic
lymph nodes in this patient could have been a result of either dis-
ease process. The findings of increased SUVmax in a lymph node
while indicating an underlying pathology, is not specific for neo-
plasm versus inflammation. Therefore, the findings of abnormal
activity in the lymph nodes were more sensitive when there was
a known primary malignancy. Lastly, this study has limitations
inherent in those that are retrospective. Ideally, the PET/CT and
contrast-enhanced CT scans would have been performed in the
same day in order to determine which imaging modality is more
effective at detection of the lymph nodes.
CONCLUSION
This study finds that PET/CT is more accurate in the detection of
pathologic cardiophrenic lymph nodes than CT, particularly when
they are smaller than 1 cm. The size of the lymph node was not
found to be important as an exclusion criteria for pathology while
the presence of multiple lymph nodes in this region was consid-
ered more suspicious for disease. In addition, the degree of activity
as measured by the SUVmax was thought to directly correlate with
the presence of disease. While the presence of abnormal cardio-
phrenic lymph nodes did not impact staging or management in
six of the patients, it did have the potential to impact management
in three of them, most notably in the patient with squamous cell
carcinoma of the lung. We propose that the IASLC lung cancer
TNM staging classification be revised to include the presence of
cardiophrenic lymph nodes in the nodal map. Also, while biopsies
of these nodes can prove challenging given the location, there may
be alternatives to the traditional VATS, such as transabdominal
CPLND or ultrasound guided biopsy.
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